{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:18:37Z","timestamp":1790965117135,"version":"4.1.0"},"reference-count":55,"publisher":"FapUNIFESP (SciELO)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Neuro-Psiquiatr."],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:p>Neuromyelitis optica (NMO) is an inflammatory disease of the central nervous system characterized by severe optic neuritis and transverse myelitis, usually with a relapsing course. Aquaporin-4 antibody is positive in a high percentage of NMO patients and it is directed against this water channel richly expressed on foot processes of astrocytes. Due to the severity of NMO attacks and the high risk for disability, treatment should be instituted as soon as the diagnosis is confirmed. There is increasing evidence that NMO patients respond differently from patients with multiple sclerosis (MS), and, therefore, treatments for MS may not be suitable for NMO. Acute NMO attacks usually are treated with high dose intravenous corticosteroid pulse and plasmapheresis. Maintenance therapy is also required to avoid further attacks and it is based on low-dose oral corticosteroids and non-specific immunosuppressant drugs, like azathioprine and mycophenolate mofetil. New therapy strategies using monoclonal antibodies like rituximab have been tested in NMO, with positive results in open label studies. However, there is no controlled randomized trial to confirm the safety and efficacy for the drugs currently used in NMO.<\/jats:p>","DOI":"10.1590\/s0004-282x2012000100012","type":"journal-article","created":{"date-parts":[[2012,1,4]],"date-time":"2012-01-04T02:56:19Z","timestamp":1325645779000},"page":"59-66","source":"Crossref","is-referenced-by-count":42,"title":["Treatment of neuromyelitis optica: an evidence based review"],"prefix":"10.1590","volume":"70","author":[{"given":"Douglas","family":"Sato","sequence":"first","affiliation":[{"name":"Tohoku University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagoberto","family":"Callegaro","sequence":"additional","affiliation":[{"name":"University of S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Aur\u00e9lio","family":"Lana-Peixoto","sequence":"additional","affiliation":[{"name":"Federal University of Minas Gerais, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Fujihara","sequence":"additional","affiliation":[{"name":"Tohoku University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk DM","year":"1999","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon VA","year":"2004","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/archneur.63.7.964","article-title":"Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression","volume":"63","author":"Pittock SJ","year":"2006","journal-title":"Arch Neurol","ISSN":"https:\/\/id.crossref.org\/issn\/0003-9942","issn-type":"print"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk DM","year":"2006","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/1352458506071174","article-title":"Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica","volume":"13","author":"Watanabe S","year":"2007","journal-title":"Mult Scler","ISSN":"https:\/\/id.crossref.org\/issn\/1352-4585","issn-type":"print"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1212\/WNL.51.4.1219","article-title":"Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine","volume":"51","author":"Mandler RN","year":"1998","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1177\/1352458507077189","article-title":"Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis","volume":"13","author":"Watanabe S","year":"2007","journal-title":"Mult Scler","ISSN":"https:\/\/id.crossref.org\/issn\/1352-4585","issn-type":"print"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","article-title":"Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre","volume":"130","author":"Takahashi T","year":"2007","journal-title":"Brain","ISSN":"https:\/\/id.crossref.org\/issn\/0006-8950","issn-type":"print"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/brain\/awn240","article-title":"Antibody to aquaporin-4 in the long-term course of neuromyelitis optica","volume":"131","author":"Jarius S","year":"2008","journal-title":"Brain","ISSN":"https:\/\/id.crossref.org\/issn\/0006-8950","issn-type":"print"},{"key":"ref10","series-title":"Acute pain management: operative or medical procedures and trauma","year":"1993"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1378\/chest.129.1.174","article-title":"Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force","volume":"129","author":"Guyatt G","year":"2006","journal-title":"Chest","ISSN":"https:\/\/id.crossref.org\/issn\/0012-3692","issn-type":"print"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-5728(01)00330-7","article-title":"Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders","volume":"117","author":"Gold R","year":"2001","journal-title":"J Neuroimmunol","ISSN":"https:\/\/id.crossref.org\/issn\/0165-5728","issn-type":"print"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s004150070172","article-title":"Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials","volume":"247","author":"Brusaferri F","year":"2000","journal-title":"J Neurol","ISSN":"https:\/\/id.crossref.org\/issn\/0340-5354","issn-type":"print"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00417-010-1344-7","article-title":"Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica","volume":"248","author":"Nakamura M","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol","ISSN":"https:\/\/id.crossref.org\/issn\/0721-832X","issn-type":"print"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"453","DOI":"10.7326\/0003-4819-131-6-199909210-00011","article-title":"Therapeutic plasma exchange: an update from the Canadian Apheresis Group","volume":"131","author":"Clark WF","year":"1999","journal-title":"Ann Intern Med","ISSN":"https:\/\/id.crossref.org\/issn\/0003-4819","issn-type":"print"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/jca.20249","article-title":"Clinical applications of therapeutic apheresis","volume":"25","author":"Balogun RA","year":"2010","journal-title":"J Clin Apher"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1089\/jop.2009.0150","article-title":"Anti-aquaporin-4 antibody-positive optic neuritis treated with double-filtration plasmapheresis","volume":"26","author":"Yoshida H","year":"2010","journal-title":"J Ocul Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/8756-3320","issn-type":"print"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2141.1978.tb01078.x","article-title":"Intensive plasma exchange on the cell separator: effects on serum immunoglobulins and complement components","volume":"38","author":"Keller AJ","year":"1978","journal-title":"Br J Haematol","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1048","issn-type":"print"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1046\/j.1537-2995.1989.29289146829.x","article-title":"Complications of plasma exchange","volume":"29","author":"Sutton DM","year":"1989","journal-title":"Transfusion","ISSN":"https:\/\/id.crossref.org\/issn\/0041-1132","issn-type":"print"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1212\/WNL.58.1.143","article-title":"Plasma exchange for severe attacks of CNS demyelination: predictors of response","volume":"58","author":"Keegan M","year":"2002","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1744-9987.2009.00780.x","article-title":"Intermittent plasmapheresis prevents recurrence in neuromyelitis optica","volume":"13","author":"Miyamoto K","year":"2009","journal-title":"Ther Apher Dial"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1212\/WNL.0b013e318207b1f6","article-title":"Evidence-based guideline update. Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"76","author":"Cortese I","year":"2011","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","article-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker BG","year":"1999","journal-title":"Ann Neurol","ISSN":"https:\/\/id.crossref.org\/issn\/0364-5134","issn-type":"print"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jocn.2010.07.141","article-title":"Therapeutic efficacy of double filtration plasmapheresis in patients with anti-aquaporin-4 antibody-positive multiple sclerosis","volume":"18","author":"Munemoto M","year":"2011","journal-title":"J Clin Neurosci"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jocn.2010.05.030","article-title":"The rescue effect of plasma exchange for neuromyelitis optica","volume":"18","author":"Wang KC","year":"2011","journal-title":"J Clin Neurosci"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/jca.20240","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis","volume":"25","author":"Szczepiorkowski ZM","year":"2010","journal-title":"J Clin Apher"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s11940-010-0071-z","article-title":"Neuromyelitis optica","volume":"12","author":"Carroll W","year":"2010","journal-title":"Curr Treat Options Neurol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2217\/pgs.09.155","article-title":"Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications","volume":"11","author":"Higgs JE","year":"2010","journal-title":"Pharmacogenomics"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/archneurol.2010.203","article-title":"Neuromyelitis optica treatment: analysis of 36 patients","volume":"67","author":"Bichuetti DB","year":"2010","journal-title":"Arch Neurol","ISSN":"https:\/\/id.crossref.org\/issn\/0003-9942","issn-type":"print"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1212\/WNL.0b013e3181fc2788","article-title":"No relapse of neuromyelitis optica during drug-induced B-lymphopenia with hypogammaglobulinemia","volume":"75","author":"Tanaka Y","year":"2010","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree BA","year":"2005","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"457","DOI":"10.5692\/clinicalneurol.49.457","article-title":"Trial of rituximab in three patients with neuromyelitis optica","volume":"49","author":"Imamura H","year":"2009","journal-title":"Rinsho Shinkeigaku","ISSN":"https:\/\/id.crossref.org\/issn\/0009-918X","issn-type":"print"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10072-007-0823-z","article-title":"Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease)","volume":"28","author":"Capobianco M","year":"2007","journal-title":"Neurol Sci"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jocn.2010.12.011","article-title":"Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels","volume":"18","author":"Nakashima I","year":"2011","journal-title":"J Clin Neurosci"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"Jacob A","year":"2008","journal-title":"Arch Neurol","ISSN":"https:\/\/id.crossref.org\/issn\/0003-9942","issn-type":"print"},{"key":"ref36","article-title":"Impact of rituximab on relapse rate and disability in neuromyelitis optica","author":"Bedi GS","year":"2011","journal-title":"Mult Scler","ISSN":"https:\/\/id.crossref.org\/issn\/1352-4585","issn-type":"print"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer HL","year":"2011","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref38","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","author":"Kim S-H","year":"2011","journal-title":"Arch Neurol","ISSN":"https:\/\/id.crossref.org\/issn\/0003-9942","issn-type":"print"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1212\/01.WNL.0000095425.84407.39","article-title":"The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"61","author":"Goodin DS","year":"2003","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/archneur.63.7.957","article-title":"Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease)","volume":"63","author":"Weinstock-Guttman B","year":"2006","journal-title":"Arch Neurol","ISSN":"https:\/\/id.crossref.org\/issn\/0003-9942","issn-type":"print"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/rheumatology\/kei263","article-title":"Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment","volume":"45","author":"Falcini F","year":"2006","journal-title":"Rheumatology","ISSN":"https:\/\/id.crossref.org\/issn\/0080-2727","issn-type":"print"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob A","year":"2009","journal-title":"Arch Neurol","ISSN":"https:\/\/id.crossref.org\/issn\/0003-9942","issn-type":"print"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0140-6736(91)93389-Q","article-title":"The Canadian Cooperative Multiple Sclerosis Study Group","volume":"337","year":"1991","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1212\/WNL.43.5.910","article-title":"Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group","volume":"43","author":"Weiner HL","year":"1993","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref45","first-page":"172","article-title":"Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica","volume":"35","author":"Mok CC","year":"2008","journal-title":"J Rheumatol","ISSN":"https:\/\/id.crossref.org\/issn\/0315-162X","issn-type":"print"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/ncprheum0818","article-title":"Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus","volume":"4","author":"Birnbaum J","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jns.2006.10.008","article-title":"Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination","volume":"252","author":"Warabi Y","year":"2007","journal-title":"J Neurol Sci","ISSN":"https:\/\/id.crossref.org\/issn\/0022-510X","issn-type":"print"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1620\/tjem.223.211","article-title":"Therapeutic efficacy of interferon beta-1b in Japanese patients with optic-spinal multiple sclerosis","volume":"223","author":"Shimizu Y","year":"2011","journal-title":"Tohoku J Exp Med","ISSN":"https:\/\/id.crossref.org\/issn\/0040-8727","issn-type":"print"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1468-1331.2009.02897.x","article-title":"Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis","volume":"17","author":"Uzawa A","year":"2010","journal-title":"Eur J Neurol","ISSN":"https:\/\/id.crossref.org\/issn\/1351-5101","issn-type":"print"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/1352458506070732","article-title":"Immunosuppressive therapy is more effective than interferon in neuromyelitis optica","volume":"13","author":"Papeix C","year":"2007","journal-title":"Mult Scler","ISSN":"https:\/\/id.crossref.org\/issn\/1352-4585","issn-type":"print"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","article-title":"Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers","volume":"67","author":"Palace J","year":"2010","journal-title":"Arch Neurol","ISSN":"https:\/\/id.crossref.org\/issn\/0003-9942","issn-type":"print"},{"key":"ref52","series-title":"Mayo Clinic: An open label study of the effects of eculizumab in neuromyelitis optica"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen P","year":"2006","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1017\/S0317167100053932","article-title":"Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG)","volume":"31","author":"Bakker J","year":"2004","journal-title":"Can J Neurol Sci","ISSN":"https:\/\/id.crossref.org\/issn\/0317-1671","issn-type":"print"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00415-003-0979-2","article-title":"A case of relapsing neuromyelitis optica treated with glatiramer acetate","volume":"250","author":"Bergamaschi R","year":"2003","journal-title":"J Neurol","ISSN":"https:\/\/id.crossref.org\/issn\/0340-5354","issn-type":"print"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/anp\/v70n1\/a12v70n1.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T19:21:23Z","timestamp":1561144883000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-282X2012000100012&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0004-282X2012000100012"],"URL":"https:\/\/doi.org\/10.1590\/s0004-282x2012000100012","relation":{},"ISSN":["0004-282X"],"issn-type":[{"value":"0004-282X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}